{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Potential Risk of', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Clinical Significance', 'Investigational Product (IP) [DTG and 3TC]', 'Refer to Investigator Brochures (IBs) for additional information', 'with ABC/3TC or DTG/ABC/3TC.', '3TC: Current treatment guidelines [DHHS, 2018; EACS, 2017] do', 'not recommend monotherapy with 3TC for participants with HBV', 'infection, which is what participants randomised to DTG/3TC FDC,', 'would effectively be receiving. Emergence of HBV variants', 'associated with resistance to 3TC has been reported in HIV-1-', 'infected participants who have received 3TC-containing', 'antiretroviral regimens in the presence of concurrent infection with', 'HBV. Additionally, discontinuation of 3TC in HBV co-infected', 'participants can result in severe exacerbations of hepatitis B.', 'DTG: Psychiatric', 'DTG: Psychiatric disorders including suicidal ideation and', \"Participants who in the investigator's judgment, pose a significant\", 'disorders', 'behaviours are common in people living with HIV. Events of suicidal', 'suicidality risk, are excluded from participating.', 'ideation, attempt, behaviour and completion were observed in', 'Because of the elevated risk in the population of people living with', 'clinical studies of DTG, primarily in participants with a pre-existing', 'HIV, treatment emergent assessment of suicidality will be monitored', 'history of depression or other psychiatric illness. The psychiatric', 'during this study through the end of the continuation phase.', 'profile for DTG (including suicidality, depression, bipolar and', 'Investigators are advised to consider mental health consultation or', 'hypomania, anxiety and abnormal dreams) was similar to RAL- or', 'referral for participants who experience signs of suicidal ideation or', 'favourable compared with EFV- based regimens.', 'behaviour (See Section 8.2.5).', 'The reporting rate for insomnia was statistically higher for blinded', 'DTG+ abacavir/lamivudine (ABC/3TC) compared to EFV/TDF/FTC', 'The participant informed consent form includes information on the', 'in ING114467; however, this was not duplicated in any other Phase', 'risk of depression and suicidal ideation and behaviour.', 'llb/III study conducted with DTG.', 'DTG: Increased rates', 'Virologically suppressed participants switching from stable ART to', 'Participants with any switch to a second line regimen due to', 'of virologic failure/', 'DTG/3TC FDC may experience virologic failure/breakthrough and', 'previous virologic failure and participants with evidence of', '27']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Potential Risk of', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Clinical Significance', 'Investigational Product (IP) [DTG and 3TC]', 'Refer to Investigator Brochures (IBs) for additional information', 'Observed Resistance', 'development of resistance.', 'pre-existing viral resistance mutation (including M184I/V) are', 'DTG: Week 96 and Week 144 analyses for the Phase III/IIIb clinical', 'excluded from this study.', 'studies supported the efficacy findings from earlier analyses, and', 'demonstrated robust maintenance of viral suppression with no', 'Genotypic resistance testing results be reviewed by ViiV Virology', 'finding of HIV-1 resistance in treatment-na\u00efve participants.', 'to ensure participants with exclusionary mutations are not', 'randomized.', '3TC: M184V is the common single mutation that leads to full', 'resistance to 3TC.', 'Participants will have HIV-1 RNA measured at routine study visits.', 'An independent data monitoring committee (IDMC) will be instituted', 'to ensure external objective medical and/or statistical review of', 'efficacy.', 'DTG: Theoretical', 'Co-administration of DTG may increase dofetilide/pilsicainide and', 'The co-administration of DTG with dofetilide, pilsicainide or', 'serious drug interaction', 'fampridine plasma concentration via inhibition of organic cation', 'fampridine is prohibited in the study (Section 11.6).', 'with dofetilide,', 'transporter (OCT-2), resulting in potentially life-threatening toxicity.', 'pilsicainide and', 'fampridine', 'DTG and 3TC: Renal', 'DTG: Mild elevations of creatinine have been observed with DTG', 'Specific/detailed toxicity management guidance is provided for', 'function', 'which are related to a likely benign effect on creatinine secretion', 'participants who develop a decline in renal function (Section', 'with inhibition of OCT-2. DTG has been shown to have no', '11.3.1.3).', 'significant effect on glomerular filtration rate (GFR) or effective renal', 'plasma flow.', 'Creatinine clearance is calculated in all participants prior to initiating', 'therapy and renal function (creatinine clearance and serum', '3TC: 3TC is eliminated by renal excretion and exposures increase', 'phosphate) will be monitored at all subsequent study visits.', 'in participants with renal dysfunction. 3TC is not recommended to', 'treat participants with a creatinine clearance <50 mL/min.', 'Participants with creatinine clearance <30 mL/min are excluded from', 'participation in this study. Safety events, including laboratory', 'toxicities will be monitored closely in participants with creatinine', 'clearance between 30-49 mL/min, as outlined in the Schedule of', 'Activities table.', '28']\n\n###\n\n", "completion": "END"}